Yesterday, Nov. 5, 2015, 68 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.04 to $15,303,456.72.

Highlighted Stocks Traded by Insiders:

Village Super Market (VLGEA) - FREE Research Report

Estate of Perry Sumas, who is Shareholder at Village Super Market, sold 2,012 shares at $25.36 on Nov. 5, 2015. Following this transaction, the Shareholder owned 801,241 shares meaning that the stake was reduced by 0.25% with the 2,012-share transaction.

The shares most recently traded at $25.94, up $0.58, or 2.24% since the insider transaction. Historical insider transactions for Village Super Market go as follows:

  • 4-Week # shares sold: 34,342
  • 12-Week # shares sold: 94,658
  • 24-Week # shares sold: 190,431

The average volume for Village Super Market has been 25,800 shares per day over the past 30 days. Village Super Market has a market cap of $250.8 million and is part of the services sector and retail industry. Shares are down 6.83% year-to-date as of the close of trading on Thursday.

Village Super Market, Inc. operates a chain of supermarkets in the United States. Its stores feature specialty departments, such as onsite bakery, an expanded delicatessen, natural and organic foods, ethnic and international foods, prepared foods, and pharmacies. The stock currently has a dividend yield of 3.92%. The company has a P/E ratio of 11.8. Currently, there are no analysts who rate Village Super Market a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VLGEA - FREE

TheStreet Quant Ratings rates Village Super Market as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Village Super Market Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AmerisourceBergen (ABC) - FREE Research Report

Clark Gina, who is Executive Vice President at AmerisourceBergen, sold 508 shares at $97.51 on Nov. 5, 2015. Following this transaction, the Executive Vice President owned 8,202 shares meaning that the stake was reduced by 5.83% with the 508-share transaction.

The shares most recently traded at $96.77, down $0.74, or 0.76% since the insider transaction. Historical insider transactions for AmerisourceBergen go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 1,781
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 1,781
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 3,493

The average volume for AmerisourceBergen has been 2.4 million shares per day over the past 30 days. AmerisourceBergen has a market cap of $21.1 billion and is part of the services sector and wholesale industry. Shares are up 8.57% year-to-date as of the close of trading on Thursday.

AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally. The stock currently has a dividend yield of 1.19%. The company has a P/E ratio of 19.6. Currently, there are 6 analysts who rate AmerisourceBergen a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABC - FREE

TheStreet Quant Ratings rates AmerisourceBergen as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and poor profit margins. Get the full AmerisourceBergen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Neogen (NEOG) - FREE Research Report

Bradley Edward, who is Vice President at Neogen, sold 24,300 shares at $55.97 on Nov. 5, 2015. Following this transaction, the Vice President owned 158,230 shares meaning that the stake was reduced by 13.31% with the 24,300-share transaction.

The shares most recently traded at $56.02, up $0.05, or 0.09% since the insider transaction. Historical insider transactions for Neogen go as follows:

  • 4-Week # shares bought: 5,060
  • 4-Week # shares sold: 6,750
  • 12-Week # shares bought: 5,060
  • 12-Week # shares sold: 6,750
  • 24-Week # shares bought: 5,560
  • 24-Week # shares sold: 11,840

The average volume for Neogen has been 196,500 shares per day over the past 30 days. Neogen has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are up 11.84% year-to-date as of the close of trading on Thursday.

Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products and services for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The company has a P/E ratio of 59.6. Currently, there are 2 analysts who rate Neogen a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NEOG - FREE

TheStreet Quant Ratings rates Neogen as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share and solid stock price performance. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Neogen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.